A new COVID-19 antiviral is on the horizon, but how does it fare?
The potential benefit in reducing severe outcomes remains unclear, says Professor Allen Cheng
A new oral antiviral might be more favourable than nirmatrelvir–ritonavir in shortening recovery times for at-risk adults with COVID-19, a study suggests.
The China-based phase III randomised trial found that the experimental drug, dubbed VV116, was at least as good as — if not better than — nirmatrelvir–ritonavir (Paxlovid) in reducing duration of illness but had fewer side effects and drug–drug interactions.
